SG11201407498RA - Veliparib in combination with whole brain radiation therapy for the treatment of brain metastases - Google Patents

Veliparib in combination with whole brain radiation therapy for the treatment of brain metastases

Info

Publication number
SG11201407498RA
SG11201407498RA SG11201407498RA SG11201407498RA SG11201407498RA SG 11201407498R A SG11201407498R A SG 11201407498RA SG 11201407498R A SG11201407498R A SG 11201407498RA SG 11201407498R A SG11201407498R A SG 11201407498RA SG 11201407498R A SG11201407498R A SG 11201407498RA
Authority
SG
Singapore
Prior art keywords
international
treatment
combination
illinois
brain
Prior art date
Application number
SG11201407498RA
Inventor
Vincent L Giranda
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48576528&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201407498R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of SG11201407498RA publication Critical patent/SG11201407498RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 21 November 2013 (21.11.2013) WIPOIPCT (10) International Publication Number WO 2013/173428 A1 (51) International Patent Classification: A61K31/4184 (2006.01) A61P 35/04 (2006.01) A61K 41/00 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/041095 15 May 2013 (15.05.2013) English English (30) Priority Data: 61/647,329 15 May 2012 (15.05.2012) US (71) Applicant: ABBVIE INC. [US/US]; 1 North Waukegan Road, North Chicago, Illinois 60064 (US). (72) Inventor: GIRANDA, Vincent L.; 272 S. Fork Dr., Gurnee, Illinois 60031 (US). (74) Agents: STEELE, Susan et al.; 100 Abbott Park Road, Bid AP06A-1/V377, Abbott Park, Illinois 60064 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: VELIPARIB IN COMBINATION WITH WHOLE BRAIN RADIATION THERAPY FOR THE TREATMENT OF BRAIN METASTASES Observed vs. Expected Survival - NSCLC oo CJ m i> Predicted Overall Survival (Case I Controlled) Censored Observation Pts at Risk Predicted Observed 0 1 60 ' 120 ! 180 ! 240 1 300 360 ! 1 420 480 1 1 540 1 600 * 660 * 720 ! 780 1 840 1 900 30 90 150 210 270 330 390 450 510 570 830 690 750 810 870 Survival Boys 32 32 32 29 10 4 32 30 30 25 21 20 17 15 12 12 10 7 7 6 3 2 1 1 1111111111 T-H © (57) Abstract: The invention relates to a method for the treatment of brain metastases from non-small cell lung cancer in subject, a ^ comprising administering subject to the an effective amount of 2-[(2R)-2-methylpyrrolidin-2-yl]-lH-benzimidazole-4-carboxamide, Q or a pharmaceutical^ acceptable salt thereof, in combination with an effective amount of whole brain radiation.
SG11201407498RA 2012-05-15 2013-05-15 Veliparib in combination with whole brain radiation therapy for the treatment of brain metastases SG11201407498RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261647329P 2012-05-15 2012-05-15
PCT/US2013/041095 WO2013173428A1 (en) 2012-05-15 2013-05-15 Veliparib in combination with whole brain radiation therapy for the treatment of brain metastases

Publications (1)

Publication Number Publication Date
SG11201407498RA true SG11201407498RA (en) 2014-12-30

Family

ID=48576528

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407498RA SG11201407498RA (en) 2012-05-15 2013-05-15 Veliparib in combination with whole brain radiation therapy for the treatment of brain metastases

Country Status (18)

Country Link
US (1) US20130310625A1 (en)
EP (1) EP2849750A1 (en)
JP (1) JP2015521188A (en)
KR (1) KR20150017355A (en)
CN (1) CN104602688A (en)
AU (1) AU2013262906A1 (en)
BR (1) BR112014028618A2 (en)
CA (1) CA2873119A1 (en)
CL (1) CL2014003072A1 (en)
DO (1) DOP2014000258A (en)
HK (1) HK1207984A1 (en)
IL (1) IL235389A0 (en)
MX (1) MX2014013903A (en)
PH (1) PH12014502464A1 (en)
RU (1) RU2014150506A (en)
SG (1) SG11201407498RA (en)
TW (1) TW201400113A (en)
WO (1) WO2013173428A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107073015B (en) * 2014-09-16 2020-07-21 艾伯维公司 Combination of veliparib with carboplatin and paclitaxel for the treatment of non-small cell lung cancer in smokers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
CN101370497B (en) 2006-01-17 2010-11-17 雅培制药有限公司 Combination product with PARP inhibitors and cell toxin and its uses
EP2558866B1 (en) * 2010-04-15 2016-08-17 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors

Also Published As

Publication number Publication date
RU2014150506A (en) 2016-07-10
PH12014502464A1 (en) 2014-12-22
BR112014028618A2 (en) 2017-06-27
HK1207984A1 (en) 2016-02-19
US20130310625A1 (en) 2013-11-21
CN104602688A (en) 2015-05-06
AU2013262906A1 (en) 2014-11-20
KR20150017355A (en) 2015-02-16
DOP2014000258A (en) 2015-01-15
MX2014013903A (en) 2015-01-16
JP2015521188A (en) 2015-07-27
EP2849750A1 (en) 2015-03-25
CA2873119A1 (en) 2013-11-21
CL2014003072A1 (en) 2015-02-27
TW201400113A (en) 2014-01-01
IL235389A0 (en) 2014-12-31
WO2013173428A1 (en) 2013-11-21

Similar Documents

Publication Publication Date Title
SG11201408261UA (en) Syringe
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201407340YA (en) Treatment of myelosuppression
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
SG11201408094YA (en) Neprilysin inhibitors
SG11201407200TA (en) Liquid formulation
SG11201407268SA (en) Nuclear transport modulators and uses thereof
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201810177VA (en) Pet-imaging immunomodulators
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201408240TA (en) Treatment of motor and movement disorder side effects associated with parkinson's disease treatments
SG11201908602UA (en) Combination therapy for the treatment of solid and hematological cancers
SG11201407368VA (en) Drug for preventing and/or treating polycystic kidney disease
SG11201402986RA (en) Kinase inhibitors
SG11201805755SA (en) Methods of administering hepcidin
SG11201408641UA (en) Phenoxyethyl piperidine compounds
SG11201406787TA (en) Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies
SG11201810143PA (en) Exon skipping oligomers for muscular dystrophy
SG11201408509PA (en) Racecadotril lipid compositions